In adults with obesity and type 2 diabetes, survodutide 3.6 mg weekly reduced body weight by 8.2% at week 76, compared with 3.9% with placebo (P<0.001).
In plain wordsIn adults with obesity and type 2 diabetes, survodutide 3.6 mg weekly led to more weight loss than placebo at week 76.
- Peptide
- Survodutide
- Outcome
- DecreasePercent change in body weight at week 76
- Study
n: not reported in source
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- 3.6 mg once weekly · subcutaneous · 76 weeksAs given in this study (human).
Measurements
- Mean weight change
- −8.2%
- survodutide 3.6 mg
- Mean weight change
- −3.9%
- placebo
Source sentences
The mean weight change at week 76 according to the treatment-regimen estimand (which assessed effects regardless of whether the trial regimen was discontinued or interrupted or whether other antiobesity therapies were used) was -8.2% (95% confidence interval [CI], -9.2 to -7.2) in the 3.6-mg group
4 context sentences(design, population, supporting numbers)
-3.9% (95% CI, -4.9 to -2.9) in the placebo group
(P<0.001 for all comparisons with placebo).
In this multinational, double-blind, phase 3 trial involving adults with type 2 diabetes and a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 27 or more, we randomly assigned participants in a 1:1:1 ratio to receive once-weekly subcutaneous survodutid…
Among 752 participants (250 in the 3.6-mg survodutide group, 251 in the 6.0-mg survodutide group, and 251 in the placebo group), the mean age at baseline was 55.7 years, and the mean BMI was 36.5; 49.3% were men.